A--PREVENT IDIQ MATO RFP
Award Details
- Contract Award Date: Jan 24, 2024
- Contract Award Number: 75N91024D00004
- Task/Delivery Order Number:
- Contractor Awarded Unique Entity ID: S3GMKS8ELA16
- Contractor Awarded Name: THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM
- Contractor Awarded Address: Houston, TX 77030 USA
- Base and All Options Value (Total Contract Value): $149,995,000.00
General Information
- Contract Opportunity Type: Award Notice (Updated)
- Updated Published Date: Jan 31, 2024 04:51 pm EST
- Original Published Date: Jan 29, 2024 09:43 am EST
- Inactive Policy: 15 days after contract award date
- Updated Inactive Date: Feb 08, 2024
- Original Inactive Date: Feb 07, 2024
- Initiative:
- None
Classification
- Original Set Aside:
- Product Service Code:
- NAICS Code:
- 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
- Place of Performance: Houston , TX 77030USA
Description
PREVENT EFFICACY Pool: This contract supports the PREVENT Cancer Preclinical Drug Development Program,
which provides a structured approach to drug and vaccine development, from discovery to the clinic. This contract is a
part of a multiple-award Indefinite Delivery Indefinite Quantity (IDIQ) pool to procure services related to Preclinical
Efficacy and Intermediate Endpoint Biomarkers, which is also referred to as the Efficacy Pool.
Attachments/Links
Contact Information
Contracting Office Address
- OFFICE OF ACQUISITIONS 31Center Dr. 11A35P
- Bethesda , MD 20892
- USA
Primary Point of Contact
- TAYLOR, RICHARD
- rich.taylor@nih.gov
- Phone Number +1 717 339 9735
Secondary Point of Contact
History
- Feb 08, 2024 11:55 pm ESTAward Notice (Updated)
- Jan 29, 2024 09:43 am ESTAward Notice (Original)
- Mar 15, 2023 11:58 pm EDTSolicitation (Updated)